Revenue: Up 18% in the six months ended September 30 to $951.2 million.
Net profit after tax: Up 43% to $153.2m.
Main takeaway: The listed respiratory healthcare company will not be drawn on the potential impact of US tariffs on Mexico, where the company has a large manufacturing facility.
The boss of Fisher & Paykel Healthcare has refused to be drawn into any speculation on the possible impact of United States President-elect Donald Trump vowing to impose a 25% tariff on all products coming from Mexico.
The listed respiratory healthcare company today reported record half-year revenue
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
Revenue: Up 18% in the six months ended September 30 to $951.2 million.
Net profit after tax: Up 43% to $153.2m.
Main takeaway: The listed respiratory healthcare company will not be drawn on the potential impact of US tariffs on Mexico, where the company has a large manufacturing facility.
